Nutri-Pharm
Established in 1999 and based in Melbourne, Australia, the company develops topical antimicrobial technologies intended to address antimicrobial drug resistance (AMR). Its approach emphasises multi-component formulations composed of well-known, low-toxicity organic compounds, targeted activity against AMR pathogens and resistance mechanisms, and formulation strategies intended for non-prescription (OTC) use. Research activities include microencapsulation, nanocellulose-based carriers, antimicrobial polymer treatments, and in vitro efficacy and biofilm testing. The company seeks industry partnerships and investors for product development and commercialisation.
Industries
Nr. of Employees
small (1-50)
Nutri-Pharm
102 Myers Road, Bittern, Vic, 3918, Australia (registered address); Research facility located in Hastings, Melbourne. ABN: 37 091 353 794
Products
Topical multi-component antimicrobial ointment (development candidate)
A topical ointment formulation combining multiple antimicrobial components designed for antibacterial, antifungal, anti-inflammatory and wound-healing activity; development-stage testing reports in vitro CFU reductions against multiple AMR species.
Aqueous topical wound formulation (development)
An aqueous-based topical formulation designed for wound use with multiple antimicrobial components and wound-healing/anti-inflammatory properties; described as under development.
Microencapsulation technology for stabilisation and delivery
Microencapsulation processes to enhance stability, versatility and controlled delivery of antimicrobial components for topical and consumer products.
Nanocellulose antimicrobial carrier
Nanocellulose-based material demonstrated to retain active antimicrobial molecules at higher levels than standard cellulose, proposed for multiple commercial applications.
Antimicrobial-treated polymers and surface coatings
Polymer treatment processes shown in testing to reduce biofilm-associated mass compared with untreated controls.
Topical multi-component antimicrobial ointment (development candidate)
A topical ointment formulation combining multiple antimicrobial components designed for antibacterial, antifungal, anti-inflammatory and wound-healing activity; development-stage testing reports in vitro CFU reductions against multiple AMR species.
Aqueous topical wound formulation (development)
An aqueous-based topical formulation designed for wound use with multiple antimicrobial components and wound-healing/anti-inflammatory properties; described as under development.
Microencapsulation technology for stabilisation and delivery
Microencapsulation processes to enhance stability, versatility and controlled delivery of antimicrobial components for topical and consumer products.
Nanocellulose antimicrobial carrier
Nanocellulose-based material demonstrated to retain active antimicrobial molecules at higher levels than standard cellulose, proposed for multiple commercial applications.
Antimicrobial-treated polymers and surface coatings
Polymer treatment processes shown in testing to reduce biofilm-associated mass compared with untreated controls.
Services
R&D collaboration and partnership services to co-develop antimicrobial carriers, treated polymers, and topical formulations for commercial applications.
R&D collaboration and partnership services to co-develop antimicrobial carriers, treated polymers, and topical formulations for commercial applications.
Expertise Areas
- Topical antimicrobial formulation
- Antimicrobial materials and coatings
- Microencapsulation and controlled-release systems
- Nanocellulose-based delivery systems
Key Technologies
- Microencapsulation
- Nanocellulose carriers
- Antimicrobial polymer treatments and coatings
- Biofilm disruption assays
News & Updates
Company announced upcoming launches from its development pipeline.
Board announcement of a new CEO tasked with driving sales or licensing of product technologies and increasing awareness of intangible IP assets.
Announcement of engagement with a university-affiliated medicines manufacturing innovation centre to assist in product development.
Public release describing the launch of a microencapsulation technology developed in association with an external manufacturing innovation centre.
Publication of an investor business case document describing a topical antimicrobial project intended to address AMR.
Company announced upcoming launches from its development pipeline.
Board announcement of a new CEO tasked with driving sales or licensing of product technologies and increasing awareness of intangible IP assets.
Announcement of engagement with a university-affiliated medicines manufacturing innovation centre to assist in product development.
Public release describing the launch of a microencapsulation technology developed in association with an external manufacturing innovation centre.
Publication of an investor business case document describing a topical antimicrobial project intended to address AMR.